What is MabThera infusion?
MabThera is used to treat non- Hodgkin’s lymphoma and chronic lymphocytic leukaemia. MabThera works by binding to a protein on the surface of certain white blood cells known as B lymphocytes. During the process of binding to the protein, the abnormal growth of the B lymphocytes is stopped.
Is MabThera the same as rituximab?
Rituximab is a targeted cancer drug and is also known by its brand names MabThera, Rixathon and Truxima. It is a treatment for: chronic lymphocytic leukaemia (CLL)
What is Rituxan infusion used to treat?
Rituximab injection (Rituxan) is used to treat pemphigus vulgaris (a condition that causes painful blisters on the skin and the lining the mouth, nose, throat and genitals). Rituximab injection products are in a class of medications called monoclonal antibodies.
How long does Rituxan infusion take to work?
Most rheumatoid arthritis patients will notice some improvement in their symptoms, such as improvement in their levels of pain and inflammation, within 16 weeks of starting treatment with Rituxan.
How do you give MabThera?
MabThera should be administered as two 500 mg IV infusions separated by two weeks, followed by a 500 mg IV infusion every 6 months thereafter. Patients should receive MabThera for at least 24 months after achievement of remission (absence of clinical signs and symptoms).
How long is non Hodgkin’s lymphoma treated?
A short course of treatment usually takes about 6 to 12 weeks. Or you might have a longer course of chemotherapy and a targeted drug, without radiotherapy. Whether you have radiotherapy depends on factors such as where the lymphoma is in the body and how fit you are.
Who makes MabThera?
The drug was developed by Biogen Idec and is co-promoted by Genentech, a subsidiary of Roche Group. Rituxan was approved by the US Food and Drug Administration (FDA) in 1997 for treating non-Hodgkin’s lymphoma. The drug received EU approval in June 1998. It is being sold under the trade name MabThera.
Is Rituxan a chemotherapy?
RITUXAN is not chemotherapy RITUXAN is a type of antibody therapy that can be used alone or with chemotherapy. They work in different ways to find and attack the cells where cancer starts. RITUXAN targets and attaches to the CD20 protein found on the surface of blood cells with cancer and some healthy blood cells.
How long does Rituxan last?
Rituxan can provide up to 6 months of symptom improvement from 1 course of treatment (2 infusions given 2 weeks apart).
Can I eat during RITUXAN infusion?
There are no special rules for what you can eat or drink before, during, or after an infusion. Some people like to eat before or bring a snack along.
How is Mabthera administered?
MabThera is given as an infusion (drip) into a vein. Patients with blood cancers can switch to an injection given under the skin after they have received one full dose of the infusion. Before each infusion or injection, the patient should be given an antihistamine (to prevent allergic reactions) and an anti-pyretic (a medicine for fever).
What is the Mabthera subcutaneous formulation?
MabThera subcutaneous formulation contains recombinant human hyaluronidase (rHuPH20), an enzyme used to increase the dispersion and absorption of co-administered substances when administered subcutaneously. Rituximab binds specifically to the transmembrane antigen, CD20, a non-glycosylated phosphoprotein, located on pre-B and mature B lymphocytes.
How is Mabthera administered during maintenance treatment for folliculitis?
In stage 2, MabThera subcutaneous formulation at a fixed dose of 1400 mg was administered as subcutaneous injection during maintenance treatment, after at least one cycle of MabThera intravenous formulation to FL patients who had previously responded to MabThera intravenous formulation in induction.
Can Mabthera be taken with glucocorticoids?
Premedication with glucocorticoids should be considered if MabThera is not given in combination with glucocorticoid-containing chemotherapy. The recommended dose of MabThera subcutaneous formulation used for adult patients is a subcutaneous injection at a fixed dose of 1400 mg irrespective of the patient’s body surface area.